Nonopioid Pain Management

Chris Robinson, MD, PhD, joined Drug Topics to discuss the importance of education in newly explored technologies for the treatment of pain.

Researchers investigated the pharmacological management of chronic orofacial pain and provided guidance on its proper treatment.

Physician with expertise in pain research discussed emerging technologies in the future of pain medicine and how they must be adapted to improve patient outcomes.

Patients with musculoskeletal pain were treated with cryotherapy spray to assess its use in providing immediate and sustained pain relief.

Researchers investigate the effects of subanesthetic doses of esketamine for the treatment of pain and cognition in patients undergoing surgery.

A discussion on the new nonopioid selective NaV1.8 pain signal inhibitor with Madison Irwin, PharmD, BCPS.

For patients with atopic dermatitis reporting moderate-to-severe scratching, researchers explored the efficacy of an AI-enabled wearable sensor with closed-loop haptic feedback.

Cardiovascular health is known to be associated with the probability of having active or developing migraine in the future.

Researchers conducted a review of clinical studies to better understand non-oral drugs for the treatment of pain related to herpes zoster.

Researchers asked adults with chronic pain and physicians their opinions on cannabis regulations.

Reducing the number of opioid prescriptions for patients with lower back pain did not result in an increased use of other, risky pain medications.

Assessing the management of chronic low back pain, researchers compared outcomes of healthy lifestyle care with current guideline-recommended care.

A recent study found that edible or smoked cannabis use predicted little variability in pain relief.

Tocilizumab-anoh is the biosimilar formulation for ACTEMRA, a medication used to treat rheumatoid arthritis, COVID-19, and other diseases.

The decision makes the selective NaV1.8 pain signal inhibitor the first new class of medicine to treat acute pain in over 20 years.

Researchers analyzed liveborn infant data from January 2020 to June 2024 to determine prevalence, cause, and treatment strategies for pain among preterm infants.

A supratherapeutic dose of 1000 ug cebranopadol was significantly less likeable compared to 40 mg oxycodone when crushed and taken intranasally.

Researchers conducted a literature review of patients’ clinical experiences with using secukinumab to treat psoriatic arthritis.

Cebranopadol is a first-in-class investigational therapy that targets the nociceptin/orphanin FQ receptor and the µ-opioid receptor.

A combination of ibuprofen and acetaminophen was found to be superior to hydrocodone and acetaminophen in managing pain after impacted mandibular third-molar extraction surgery.

XG005 from Xgene Pharmaceutical is a novel, non-opioid chemical entity that targets anti-nociceptive and anti-neuropathic pain pathways.

Check out this list of our top 5 most read nonopioid pain management stories from the year 2024.

A study found that patients with medication-overuse headache and neck pain experience earlier onset of primary headache and decreased quality of life.

Navigating Cannabis use requires more than just an understanding of the endocannabinoid system.

ATX101 from Allay Therapeutics is designed for use following total knee arthroplasty in adults and has shown positive results in multiple studies.

Most patients with reduced opioid prescriptions during cannabis use had chronic musculoskeletal pain.

Catch up on important nonopioid pain management news from November 2024.

A number of new, nonopioid osteoarthritis treatment options are either available for patients or in the development pipeline.

NSAIDS are typically the first line of treatment for axial spondyloarthritis.

Chronic pain is more prevalent—and more severe—in veterans compared with the general US population.